换一批
换一批HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
第一作者：
Paul,Haluska
第一单位：
Department of Oncology, Mayo Clinic, 200 First Street, South West, Rochester, MN 55905, USA. haluska.paul@mayo.edu
作者：
主题词
抗肿瘤药(Antineoplastic Agents);苯咪唑类(Benzimidazoles);细胞死亡(Cell Death);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);抗药性, 肿瘤(Drug Resistance, Neoplasm);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);药物协同作用(Drug Synergism);酶激活(Enzyme Activation);细胞外信号调节MAP激酶类(Extracellular Signal-Regulated MAP Kinases);女(雌)性(Female);人类(Humans);卵巢肿瘤(Ovarian Neoplasms);磷酰化(Phosphorylation);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);吡啶酮类(Pyridones);交叉感知受体(Receptor Cross-Talk);受体, IGF1型(Receptor, IGF Type 1);受体, 胰岛素(Receptor, Insulin);信号传导(Signal Transduction)
DOI
10.1158/1535-7163.MCT-08-0493
PMID
18765823
发布时间
2021-10-20
- 浏览12
Molecular cancer therapeutics
2589-98页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
